DAILYPEPTIDE GUIDE
Experimental / RUO

Ipamorelin

Ipamorelin acetate

Ipamorelin is cataloged for research literacy, with a clear separation between proposed mechanisms, marketed claims and validated human evidence.

Compare
EvidenceTier 3
RegulatoryUnapproved / RUO
SafetyUncertain or Concerning
Clinical phaseRUO
01

Overview

ClassGrowth hormone secretagogue peptide
Sponsor / developerNo approved-product sponsor
Review statusReviewed
Record IDPEP-044
02

Plain-language guide

What it was designed or studied for

Discussed or marketed in research-only contexts for Growth hormone claims, Body-composition claims. It is not approved for treating these uses.

How it works, simply

It switches on a receptor involved in appetite and growth-hormone release. Short-term hormone release does not by itself prove lasting muscle gain.

This simplified explanation is educational context, not a treatment recommendation or a substitute for the clinical evidence below.
03

Clinical mechanism

Activates the growth hormone secretagogue receptor.

Mechanism plausibility is not the same as demonstrated clinical benefit.
04

Applications

  • Growth hormone claims
  • Body-composition claims
05

Human evidence

Validated human efficacy evidence is absent, limited or not independently replicated.

Tier 3
06

Preclinical evidence

Mechanistic and preclinical findings are tracked separately and are not treated as proof of human clinical benefit.

MAP

Muscle & recovery profile

Each signal is scored independently from 0–5. There is no composite “best” score.

Growth relevance1/5
Preservation relevance1/5
Recovery relevance1/5
Mitochondrial support0/5
Connective tissue0/5
Human-data depth1/5
Safety confidence1/5
Evidence–hype gap4/5

Evidence classes

  • Phase 1 / early human evidence
  • Preclinical animal evidence
  • Anecdotal report
  • Marketing claim

What has been studied

  • Growth-hormone release and other physiologic effects have been studied.

What is not established

  • No approved muscle, body-composition or recovery indication is established.

Studied populations

  • Early clinical and preclinical research populations

Major limitations

  • Muscle-specific outcomes may be secondary, exploratory or absent from available studies.
  • Findings from one population, formulation or indication should not be generalized to another.

Evidence-source categories: primary regulatory record, clinical trial registry, peer reviewed literature. These editorial source categories require record-level primary links before publication-grade citation export.

06

Regulatory status

Unapproved / RUO. Regulatory status is product- and jurisdiction-specific and does not automatically follow from an evidence score.

07

Safety

Uncertain or Concerning

  • Human safety data are incomplete
  • Product identity, sterility and dose consistency may be unknown
08

Interactions

Combination data are sparse. Absence of documented interaction evidence is not evidence of compatibility.

09

Treatment pattern

No validated human dosing or cycling protocol exists.

10

Manufacturing and quality

RUO and grey-market products may not establish identity, net content, sterility, endotoxin control or cold-chain integrity.

12

Sources

  1. 01
    Primary regulatory record

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

  2. 02
    Clinical trial registry

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

  3. 03
    Peer-reviewed literature

    Source record prepared for primary-reference linking in the Supabase-backed editorial workflow.

13

Gaps and unverified claims

  • No validated human dosing or cycling protocol exists.
  • Long-term safety and product-quality consistency remain unresolved.
14

Last reviewed

August 5, 2026 · Reviewed